Introduction
============

Reports of a newly-discovered gammaretrovirus (xenotropic murine leukemia virus-related virus; XMRV) in patients diagnosed with prostate cancer \[[@B1],[@B2]\] and chronic fatigue syndrome (CFS) \[[@B3]\] have attracted the attention of investigators throughout the retroviral research community. XMRV was initially identified in prostate tumor samples from individuals harboring a specific polymorphism in *RNASEL*, a gene important for interferon-mediated antiviral defense \[[@B1]\]. Studies describing the receptor usage and integration site preference of the virus were soon followed by a second report of XMRV infection in an unrelated cohort of prostate cancer patients \[[@B2]\]. Although an association between XMRV and the aforementioned *RNASEL*polymorphism was not found \[[@B2]\], the idea that defects in innate immunity might be linked to XMRV infection prompted others to look for the virus in patients with CFS \[[@B3]\]. Remarkably, PCR assays identified XMRV DNA in peripheral blood samples from 68 of 101 CFS patients and 8 of 218 healthy controls. These and other findings provided compelling evidence that XMRV is the first known example of an exogenous human gammaretrovirus.

In contrast, subsequent efforts to assess the prevalence of XMRV in patients with CFS and prostate cancer have reached widely disparate conclusions \[\[[@B4]\]; see also reference \[[@B5]\] for review\]. The underlying factors responsible for this discord are unclear; but from the beginning, researchers have repeatedly voiced concerns that at least some accounts of PCR-positive results are attributable to the inadvertent contamination of human specimens or reagents with mouse DNA. These concerns were revisited following a recent report by Lo *et al*. that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)\--but not XMRV\--in blood samples from CFS patients \[[@B6]\]. Such skepticism is justified by previous examples of alleged human retroviruses that later turned out to be laboratory artifacts \[[@B7]\].

Evidence for contamination of human samples
===========================================

With this history in mind, four independent studies published this week in *Retrovirology*reinforce the need to take extreme precautions in excluding mouse DNA contamination. Robinson *et al.*\[[@B8]\] performed a PCR analysis of 437 prostate tissue specimens from patients in the United Kingdom (UK), Thailand and Korea using primers that targeted the 5\'-leader region of XMRV *gag*. Initial PCR results showed that 14 of 292 samples from the UK contained XMRV or MLV-related sequences. However, 78 of the UK samples, including all 14 XMRV/MLV-positive specimens, contained amplifiable levels of LTR sequences from intercisternal A-type particles (IAPs), a class of endogenous retroelements found in the mouse genome. Similarly, Oakes and colleagues \[[@B9]\] identified 2 of 112 blood samples from CFS patients and 17 of 36 samples from healthy controls that were PCR-positive for XMRV *gag-*leader DNA, but later found that all of the XMRV-positive specimens contained amplifiable levels of mouse mitochondrial or IAP sequences. These data strongly suggest that the XMRV sequences recovered by Robinson \[[@B8]\] and Oakes \[[@B9]\] originated from mouse DNA that contaminated the study samples prior to PCR.

Evidence for contamination of PCR reagents
==========================================

A third report by Sato *et al.*\[[@B10]\] describes the detection of MLV-encoding nucleic acids in PCR reagents obtained from a commercial supplier (Invitrogen). Analyses of individual components from the PCR kit (SuperScript^®^III One-Step RT-PCR System with Platinum^®^Taq High Fidelity) suggest that the mixture of reverse transcriptase and Taq DNA polymerase supplied by the manufacturer was contaminated with MLV RNA. This contamination likely originated from a monoclonal antibody preparation used in the polymerase mixture to facilitate hot-start PCR.

Further details of the contamination found by Robinson \[[@B8]\], Oakes \[[@B9]\] and Sato \[[@B10]\] were obtained by DNA sequence analysis of the PCR-amplified products. All three studies identified sequences that that were closely related to endogenous MLV. In particular, Oakes and coworkers obtained a broad array of polytropic, modified-polytropic and xenotropic MLV-like sequences \[[@B9]\], a result strikingly similar to the findings of Lo *et al*. in their analysis of CFS patient samples \[[@B6]\]. Both Oakes and Robinson also identified subsets of amplicons that encoded a 24-nt *gag*-leader deletion previously thought to be specific for XMRV (see below). Collectively, these data show the ease with which contamination can lead to false-positive MLV/XMRV signals.

Phylogenetic support for contamination in previous studies of XMRV
==================================================================

Finally, Hué and colleagues \[[@B11]\] present multiple lines of evidence suggesting that contamination has occurred repeatedly in previous studies of XMRV. The authors begin by showing that the 24-nt *gag*-leader deletion is not unique to XMRV; PCR primers targeting the deletion readily amplified endogenous MLV sequences from 12 different inbred and wild-derived mouse strains commonly used in laboratory experiments, as well as MLV sequences present in 5 of 411 human tumor cell lines. The latter result is consistent with previous reports of xenotropic MLV contamination in human cell cultures \[\[[@B11]\] and references therein\].

Next, Hué *et al*. PCR-amplified, cloned and sequenced XMRV *gag*, *pol*and *env*segments from 22Rv1 prostate carcinoma cells, an immortalized line known to harbor multiple integrated copies of the virus. Remarkably, the 22Rv1 sequences displayed average pairwise genetic distances that equaled or exceeded those of previously-published XMRV sequences from prostate cancer \[[@B1]\] and CSF patients \[[@B3]\], despite the fact that these patients were from epidemiologically unlinked cohorts. In addition, phylogenetic analyses of the 22Rv1 and patient-derived XMRV sequences strongly suggest that the patient sequences obtained to date \[[@B1],[@B3]\] originated from one or more XMRV proviruses present in the 22Rv1 cell line \[[@B11]\].

Conclusions
===========

The reports discussed above \[[@B8]-[@B11]\] collectively identify three potential sources of contamination in PCR-based studies of XMRV: (i) MLV-encoding nucleic acids present in commercial PCR reagents, (ii) trace amounts of mouse genomic DNA in human blood and tissue samples, and (iii) DNA or RNA from human tumor cell lines infected with XMRV or other closely-related gammaretroviruses. PCR testing for IAP sequences \[[@B8],[@B9]\] should prove useful in further studies of XMRV, as well as other candidate human retroviruses, in which the confounding effects of mouse DNA contamination must be minimized. However, the findings of Hué *et al*. clearly show that contamination cannot be assessed by PCR testing for mouse DNA alone, since several human cell lines harbor xenotropic MLVs that are closely related to XMRV \[[@B11]\]. Additional findings from the Hué study suggest that previously-published XMRV sequences \[[@B1],[@B3]\] were derived from copies of the virus present in 22Rv1 cells, which likely acquired XMRV during xenografting of the tumor cells in athymic mice \[\[[@B11]\] and references therein\]. Collectively, these results cast serious doubts on the PCR evidence used to support claims of MLV-related viruses in prostate cancer and CFS patients. Future assessments of the prevalence of XMRV should include more rigorous PCR and phylogenetic tests to exclude the possibility of contamination.
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